ProCE Banner Activity

Interactive Decision Support Tool: Expert Insights on Metastatic Clear Cell Renal Cell Carcinoma Therapy Selection

Tool

Compare your choice of therapy for patients with metastatic clear cell RCC with 5 expert recommendations using this interactive decision support tool

Released: June 27, 2023

Share

Faculty

Katy Beckermann

Katy Beckermann, MD, PhD

Assistant Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Eric Jonasch

Eric Jonasch, MD

Professor, Department of GU Medical Oncology
UT MD Anderson Cancer Center 
Houston, Texas

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California

Wenxin Xu

Wenxin Xu, MD

Instructor of Medicine
Lank Center for Genitourinary Oncology
Physician
Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Tian Zhang

Tian Zhang, MD, MHS

Associate Professor
Division of Hematology and Oncology
Department of Internal Medicine
Associate Director of Clinical Research
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AVEO Pharmaceuticals, Inc.

Bristol Myers Squibb

Exelixis, Inc.

Faculty Disclosure

Primary Author

Katy Beckermann, MD, PhD

Assistant Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Katy Beckermann, MD, PhD: consultant/advisor/speaker: Alpine Bioscience, Aveo, Aravive, AstraZeneca, BMS, Exelexis, Merck, Seagen, Sanofi; researcher (paid to institution): Arsenal, Aravive, Bristol-Myers Squibb/LCFA/IASLC.

Eric Jonasch, MD

Professor, Department of GU Medical Oncology
UT MD Anderson Cancer Center 
Houston, Texas

Eric Jonasch, MD: consultant/advisor/speaker: Aveo, Aravive, Calithera, DAVA Oncology, Eisai, Exelixis, Genentech, Ipsen, Merck, NiKang, Takeda; researcher: Arrowhead, Merck, NiKang.

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California

Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Eisai, Johnson & Johnson, Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus.

Wenxin Xu, MD

Instructor of Medicine
Lank Center for Genitourinary Oncology
Physician
Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Wenxin Xu, MD: consultant/advisor/speaker: Exelixis, Jazz Pharmaceuticals.

Tian Zhang, MD, MHS

Associate Professor
Division of Hematology and Oncology
Department of Internal Medicine
Associate Director of Clinical Research
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Tian Zhang, MD, MS: consultant/advisor/speaker: Amgen, AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Dendreon, Eisai, Exelixis, Janssen, Lilly, Merck, Pfizer, PlatformQ, QED Therapeutics, Sanofi-Aventis, Seagen, Vaniam Group; researcher (paid to institution): AbbVie/StemCentrx, AstraZeneca, Janssen, Lilly, Merck, Merrimack, Mirati Therapeutics, Novartis, Pfizer, Regeneron, Tempus; Data Safety Monitoring Board: Aravive.